食源性肥胖大鼠下丘脑差异表达蛋白的蛋白质组学分析

建立食源性肥胖大鼠模型,对正常大鼠和肥胖大鼠下丘脑全蛋白进行双向凝胶电泳,产生下丘脑蛋白双向凝胶电泳图谱.对图谱进行比对分析后,从凝胶上切取差异表达的蛋白点,经胶内酶解,通过基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF-MS) 对酶解后的肽段进行分析,再经数据库（NCBInr）检索,对蛋白质进行鉴定.研究发现,正常组表达图谱可检测到1　160±15（n=5）个蛋白点,肥胖组表达图谱可检测到1　070±10 （n=5）个蛋白点,与对照组相比,匹配率大于80％.并且成功鉴定了17种差异表达蛋白质,其中有7 种在肥胖组表达上调,10种表达下调.它们分别属于代谢酶、细胞周期调控因子、抗氧化蛋白、信号传导蛋白、蛋白酶体相关蛋白、细胞骨架蛋白以及未知蛋白等. 与正常对照组相比,肥胖组的蛋白质表达存在着较大差异,通过对差异表达蛋白的分析,提示了在肥胖发生的过程中,下丘脑神经中枢经历了一个非常复杂的信号活动和特定改变,为深入认识肥胖的发病机制奠定了基础.     

APP5肽对糖尿病小鼠学习记忆功能与海马神经元蛋白表达的影响

目的研究APP5肽对糖尿病模型小鼠学习记忆能力及海马神经元蛋白表达的影响。方法用链脲佐菌素诱发小鼠糖尿病模型,应用APP5肽（0.0014 mg/kg）皮下注射治疗,5周后进行Morris水迷宫试验;小鼠脑组织海马做Akt、PI3K、P-CREB、Bcl-2、Bax、CytoC免疫组织化学染色;另一部分鼠脑海马,做Bcl-2、Bax抗体蛋白免疫印记。结果（1）水迷宫试验：糖尿病模型小鼠到达站台游动时间比正常对照组延长（P〈0.01）;而APP5肽皮下注射治疗组较DM组动物分别缩短（P〈0.01）。（2）神经免疫组织化学实验和Western blot：给予APP5肽糖尿病小鼠与对照组小鼠海马组织内神经元表达细胞存活相关蛋白及抗凋亡相关蛋白PI3K、Akt、P-CREB、Bcl-2阳性细胞数相似,明显高于糖尿病小鼠（P〈0.01）;APP5肽给予糖尿病小鼠与对照组小鼠表达凋亡蛋白Bax、cytoC阳性细胞数相似,明显少于糖尿病小鼠（P〈0.01）。Western blot结果相同。结论糖尿病小鼠海马神经元表达细胞存活相关蛋白下降,神经元表达细胞凋亡相关蛋白增加,导致其学习记忆能力下降。APP5肽应用可以使上述蛋白恢复到接近正常,从而改善糖尿病小鼠学习记忆能力。     

二氢杨梅素对2型糖尿病小鼠认知功能障碍的影响

目的：观察二氢杨梅素（DHM）对2型糖尿病（T2DM）小鼠认知功能障碍及海马中BDNF蛋白表达的影响。方法：将40只C57BL/6J小鼠首先随机分为两组：正常对照组（n=8）：普通饲料喂养;2型糖尿病模型组（n=32）：高糖高脂联合100 mg/kg的STZ处理（造模过程中死亡5只,不成功3只）。24只建模成功的小鼠随机分成3组：T2DM组、T2DM+L-DHM组和T2DM+H-DHM组,3组小鼠高糖高脂喂养,同时分别用等体积生理盐水、125 mg/（kg·d）的DHM和250 mg/（kg·d）的DHM （1次/天,灌胃）处理16周。正常对照小鼠继续普通饲料喂养,同时用等体积生理盐水（1次/天,灌胃）处理16周。16周后测定小鼠体重、空腹血糖、进行腹腔注射葡萄糖耐量实验和相关行为学实验。最后,Western blot检测各组小鼠海马中BDNF蛋白的表达。结果：高糖高脂联合100 mg/kg的STZ成功建立2型糖尿病小鼠模型。16周后,与正常对照组相比,T2DM组小鼠体重明显下降,空腹血糖显著升高,糖耐量显著异常;而T2DM+DHM组相比T2DM组小鼠体重却显著增加、空腹血糖降低,且H-DHM可显著改善T2DM小鼠糖耐量异常。行为学实验结果显示：与正常对照组相比,T2DM组小鼠学习记忆能力明显下降;与T2DM组相比,T2DM+DHM组小鼠学习记忆能力得到改善,且H-DHM组更为明显。Western blot结果显示：与对照组相比,T2DM组小鼠海马中BDNF蛋白表达显著下降,而DHM组相比T2DM组小鼠其BDNF蛋白的表达明显增加。结论：二氢杨梅素可改善2型糖尿病小鼠认知功能障碍,其机制可能通过降血糖作用,并激活海马中BDNF蛋白表达。     

黑苦荞茎叶对2型糖尿病小鼠的治疗作用及其对其胰腺、脾脏的影响

目的:观察黑苦荞茎叶(BBL)对2型糖尿病小鼠治疗作用及其对胰腺、脾脏的影响。方法:将40只SPF级雄性C57/B16小鼠随机分为正常对照组(n=10)和实验组(n=30),实验组给予高糖高脂饲料喂养1个月后,每只小鼠在禁食12h后腹腔注射链脲佐菌素35mg/kg,注射后72h取尾血测血糖≥13.8mmol/L为糖尿病小鼠。成功建立2型糖尿病(T2DM)模型的30只小鼠随机分为3组(n=10):模型对照组(DM组)、低剂量黑苦荞茎叶治疗组(DM+L)组、高剂量黑苦荞茎叶治疗(DM+H)组。对照组和模型组小鼠每日给予生理盐水灌胃,两个黑苦荞茎叶组分别给予0.21g/kg·d-1和0.42g/kg·d-1的黑苦荞茎叶灌胃,14d后杀死小鼠,取血和胰腺、脾脏,检测血清中葡萄糖(FBG)、甘油三酯(TG)、总胆固醇(TCH)、胰岛素和脾脏组织中TNF-α蛋白的含量,观察胰腺组织形态学,称量小鼠体重和脾脏重量、计算脾脏系数,检测胰腺组织中IRS-1mRNA的表达和胰腺组织内胰岛素受体底物IRS-1蛋白表达。结果:与对照组相比,模型组小鼠血清FBG、TC、TCH水平明显升高,使血胰岛素水平明显下降,脾脏组织TNF-α蛋白表达水平显著升高,胰腺组织中IRS-1mRNA表达和IRS-1的蛋白表达水平显著降低(P<0.05);与模型组相比,治疗组小鼠的血清FBG、TC、TCH水平明显降低,血胰岛素水平显著升高,小鼠脾脏系数、脾脏组织TNF-α蛋白表达水平、胰腺组织IRS-1mRNA表达和IRS-1的蛋白表达水平显著升高(P<0.05)。高剂量黑苦荞茎叶(0.42g/kg·d-1)治疗作用更加明显。结论:黑苦荞茎叶对2型糖尿病小鼠具有显著的降血糖、降血脂的治疗效果,对糖尿病小鼠胰腺、脾脏具有一定的保护作用。     

口服活性AdipoRon对2型糖尿病小鼠肝脏氧化应激的干预作用

目的：研究口服活性AdipoRon对2型糖尿病小鼠肝脏氧化应激是否有干预作用,为临床应用提供基础资料。方法：将健康雄性C57BL/6小鼠分为正常组（n=8）,糖尿病组（n=8）,AdipoRon高剂量治疗组（n=8）,Adi-poRon低剂量治疗组（n=8）,以高脂饲料喂养6周后腹腔注射40 mg/kg链脲佐菌素（STZ）诱导2型糖尿病模型,用高、低剂量的口服活性AdipoRon分别对治疗组灌胃治疗10 d后,检测相关生化指标,Western-blot法检测肝脏组织中IRS-1蛋白的表达;实时荧光定量PCR检测胰腺组织中PDX-1 mRNA的表达。结果：DM组小鼠血糖值明显高于NC组（P < 0.05）,DM+L组和DM+H组小鼠血糖值显著低于DM组。DM组小鼠肝脏组织中超氧化物歧化酶（SOD）、过氧化氢酶（CAT）活性显著低于NC组（P < 0.05）,丙二醛（MDA）及一氧化氮合酶（NOS）活性显著高于NC组（P <0.05）;DM+L组和DM+H组SOD、CAT活性明显高于DM组（P < 0.05）,MDA及NOS活性显著低于DM组（P <0.05）。肝脏组织中IRS-1的蛋白表达及胰腺PDX-1 mRNA表达显著升高,存在统计学意义（P < 0.05）。结论：口服活性AdipoRon对糖尿病小鼠肝脏组织氧化应激有一定的干预作用,能降低小鼠的血糖水平。     

糖尿病及胰岛素干预对小鼠大脑皮层SCF/KIT系统的影响

目的：探讨不同血糖水平时小鼠大脑皮层干细胞因子/受体酪氨酸激酶c-kit系统的表达。方法：成年雄性C57小鼠27只,随机分为3组（n=9）：正常对照组（CON）、糖尿病组（DM）和糖尿病＋胰岛素组（DM＋INS）。用链脲佐菌素建立糖尿病小鼠模型,Western-blot检测干细胞因子（SCF）、受体酪氮酸激酶（KIT）蛋白的表达,免疫双标显示SCF/KIT的分布情况。结果：Western-blot和免疫双标结果均显示糖尿病小鼠大脑皮层内的S（分泌型）-SCF、M（膜型）-SCF表达水平均明显降低,应用胰岛素干预后可有效逆转此种变化趋势。结论：SCF表达的下调可能是引起糖尿病脑病的发生基础之一。     

1型糖尿病小鼠肝脏的口服葡萄糖代谢及差异表达基因

目的：观察口服葡萄糖在1型糖尿病小鼠肝脏的代谢,比较1型糖尿病小鼠与正常小鼠口服葡萄糖后肝组织基因表达的差异。方法：链脲霉素（STZ）诱导C57雄性小鼠1型糖尿病模型为实验组（n=8）,正常C57雄性小鼠为对照组（n=8）。每组随机取2只,按50ml／kg给予4％葡萄糖生理盐水溶液灌胃,2h取肝组织检测基因表达谱（Mouse Genome 430 2．0Array）。每组另6只．同样剂量给予含14C标记葡萄糖。结果：糖尿病小鼠口服14C标记葡萄糖2h后,肝组织同位素水平是正常对照组的4倍。以正常对照组为参比,共有舛条基因的表达变化差异在2倍以上,其中上调基因61个,下调基因33个。根据功能基因组分析,11条差异表达基因与脂代谢、胆固醇代谢相关,其中7条上调基因与脂、胆固醇合成相关,1条下调基因与脂肪酸分解相关。结论：SIZ诱导的1型糖尿病小鼠口服葡糖后2h,肝脏脂、胆固醇合成相关基因表达增高。     

从干预SIRT1表达探究急性应激影响糖尿病小鼠葡萄糖代谢和脂肪代谢的机制

摘要 目的：从干预组蛋白去乙酰化酶（Sirtuin1, SIRT1）表达探究急性应激影响糖尿病小鼠葡萄糖代谢和脂肪代谢的机制。方法：以30只C57BL/6小鼠为研究对象,通过高脂饮食和链脲佐菌素腹腔注射诱导的T2DM 模型小鼠,然后随机分为对照组（正常小鼠+柠檬酸盐缓冲液灌胃）、糖尿病组（糖尿病小鼠+柠檬酸盐缓冲液注射）和SIRT1干预组（糖尿病小鼠+SRT1720的载体缓冲液灌胃）。通过血糖仪和胰岛素ELISA试剂盒分别检测小鼠空腹血糖、胰岛素水平。使用血液化学自动分析仪检测小鼠血清甘油三酯、总胆固醇、低密度脂蛋白（LDL）-胆固醇和高密度脂蛋白（HDL）-胆固醇水平。收集小鼠白色脂肪组织冲洗并称重比较。通过RT-PCR分析脂肪生成转录因子PPARγ和SREBP-1c、脂肪酸合成因子Fas和Ap2、脂肪酸分解因子Hsl的mRNA表达。通过蛋白印迹分析AMPK-SIRT1-PGC-1通路蛋白的表达。结果：糖尿病组较对照组空腹血糖、胰岛素水平升高（P<0.05）,SIRT1干预组较糖尿病组空腹血糖、胰岛素水平降低（P<0.05）。糖尿病组较对照组血清甘油三酯、总胆固醇、HDL-胆固醇和LDL-胆固醇升高（P<0.05）。糖尿病组较对照组附睾、腹膜后、肠系膜和腹股沟脂肪的重量升高（P<0.05）,SIRT1干预组较糖尿病组的白色脂肪重量降低（P<0.05）。SIRT1干预组较糖尿病组降低（P<0.05）。糖尿病组较对照组的血糖水平在30、60和120分钟时升高（P<0.05）,SIRT1干预组较糖尿病组各时间点血糖水平降低（P<0.05）。糖尿病组较对照组PPARγ、SREBP-1c、Fas、Ap2的mRNA表达升高（P<0.05）,HslmRNA降低（P<0.05）,SIRT1干预组较糖尿病PPARγ、SREBP-1c、Fas、Ap2的mRNA表达升高,HslmRNA降低（P<0.05）。糖尿病组较对照磷酸化AMPK、SIRT1和PGC-1的表达降低（P<0.05）,SIRT1干预组较糖尿病组磷酸化AMPK、SIRT1和PGC-1的表达升高（P<0.05）。结论：调控SIRT1高表达可激活糖尿病小鼠AMPK/PGC-1α 信号通路,同时促进脂肪分解和抑制脂肪合成而表现出抗肥胖作用。     

AdipoRon对2型糖尿病小鼠肾脏损伤的干预作用

目的：研究脂联素受体激动剂（AdipoRon）对2型糖尿病小鼠肾脏损伤的干预作用。方法：将40只SPF级雄性C57/BL6小鼠随机分为正常对照组（n=10）和实验组（n=30）：实验组给予高糖、高脂饲料喂养,联合腹腔注射小剂量链脲佐菌素（STZ）建立2型糖尿病（T2DM）小鼠模型,再随机分为3组（n=10）：模型对照（DM）组、低剂量AdipoRon治疗（DM+L）组及高剂量AdipoRon治疗（DM+H）组。检测血清中葡萄糖含量的变化;采用酶联免疫法检测小鼠血清中胰岛素受体（INSR）、胰岛素受体底物-1（IRS-1）以及肿瘤坏死因子-α（TNF-α）的蛋白质含量;HE染色镜下观察肾组织形态学变化;实时荧光定量PCR法检测肾组织胰岛素促进因子-1（PDX-1）和胰岛素（insulin）mRNA的表达;Western blot检测肾组织内磷酸化胰岛素受体底物-1（p-IRS-1）蛋白质;ELISA试剂盒检测小鼠血胰岛素含量。结果：病理学检查表明,AdipoRon可减轻2型糖尿病所致小鼠肾脏损伤。与DM组小鼠比较,DM+H组和DM+L组小鼠血糖、TNF-α水平均显著降低（P<0.05）,INSR、IRS-1和p-IRS-1表达显著上升,PDX-1和insulin mRNA表达显著上升（P<0.05,P<0.01）。结论：给予AdipoRon治疗的小鼠血糖和血清TNF-α水平显著降低,INSR,IRS-1和p-IRS-1蛋白质含量,PDX-1和insulin mRNA表达均显著上升,表明AdipoRon对2型糖尿病小鼠肾脏损伤有一定的干预作用。     

西红花水提物对实验性糖尿病小鼠血糖水平的影响

目的：观察西红花水提物对链脲佐菌素（STZ）诱导的糖尿病小鼠血糖、血脂及胰腺组织的影响。方法：采用STZ （60 mg/kg）连续2 d腹腔注射建立糖尿病小鼠模型。将造模成功后的小鼠随机分为3组（n=10）：糖尿病模型（DM）组、西红花水提物（SE）组、阳性对照二甲双胍（MH）组。另取10只正常小鼠设为正常对照（NC）组。给药组每天灌胃1次,连续6周,模型组和正常对照组灌胃生理盐水。给药期间每周测定小鼠进食量、饮水量及体重,给药6周后测定空腹血糖（FBG）、口服糖耐量（OGTT）、糖化血清蛋白（GSP）、血清胰岛素（INS）和血脂等指标的变化情况;HE染色观察胰腺组织病理变化。结果：与NC组相比,DM组进食量、饮水量、线下曲线面积、FBG、GSP以及血脂中的总胆固醇（TC）均显著升高,空腹体重、血清胰岛素（INS）及高密度脂蛋白胆固醇（HDL-c）均显著降低;与DM组相比,SE组小鼠饮水量、FBG、线下曲线面积、TC显著降低,HDL-c以及INS显著升高。病理学显示DM组胰岛结构破坏、胰岛细胞数量明显减少、胰岛血管增生、形态不规则等变化,SE能明显修复受损胰腺组织。结论：SE对链脲佐菌素诱导的糖尿病小鼠有一定降血糖、降血脂作用,可以有效改善胰腺病变的情况,提示西红花可能用于糖尿病的防治。     

Acetylcholinesterase is associated with apoptosis in β cells and contributes to insulin-dependent diabetes mellitus pathogenesis

Acetylcholinesterase (AChE) expression is pivotal during apoptosis. Indeed, AChE inhibitors partially protect cells from apoptosis. Insulin-dependent diabetes mellitus (IDDM) is characterized in part by pancreatic β-cell apoptosis. Here, we investigated the role of AChE in the development of IDDM and analyzed protective effects of AChE inhibitors. Multiple low-dose streptozotocin (MLD-STZ) administration resulted in IDDM in a mouse model. Western blot analysis, cytochemical staining, and immunofluorescence staining were used to detect AChE expression in MIN6 cells, primary β cells, and apoptotic pancreatic β cells of MLD-STZ-treated mice. AChE inhibitors were administered intraperitoneally to the MLD-STZ mice for 30 days. Blood glucose, plasma insulin, and creatine levels were measured, and glucose tolerance tests were performed. The effects of AChE inhibitors on MIN6 cells were also evaluated. AChE expression was induced in the apoptotic MIN6 cells and primary β cells in vitro and pancreatic islets in vivo when treated with STZ. Induction and progressive accumulation of AChE in the pancreatic islets were associated with apoptotic β cells during IDDM development. The administration of AChE inhibitors effectively decreased hyperglycemia and incidence of diabetes, and restored plasma insulin levels and plasma creatine clearance in the MLD-STZ mice. AChE inhibitors partially protected MIN6 cells from the damage caused by STZ treatment. Induction and accumulation of AChE in pancreatic islets and the protective effects of AChE inhibitors on the onset and development of IDDM indicate a close relationship between AChE and IDDM.     

c-Jun amino terminal kinase 1 deficient mice are protected from streptozotocin-induced islet injury

In vitro studies have implicated the c-Jun amino terminal kinase (JNK) in cytokine-induced pancreatic injury leading to a loss of insulin production and hyperglycemia. We examined the role of JNK1 in the multiple low dose streptozotocin (MLD-STZ) model in which islet injury and hyperglycemia are dependent upon T cell immunity and pro-inflammatory cytokines. MLD-STZ in wild type mice induced islet leukocyte infiltration, cytokine production, β-cell apoptosis, and hyperglycemia. In contrast, Jnk1−/− mice were substantially protected from a loss of insulin producing cells and hyperglycemia in the MLD-STZ model despite a marked islet T cell and macrophage infiltrate. Based upon several lines of evidence, this protection was attributed to a reduction in TNF-α production by infiltrating Jnk1−/− macrophages leading to reduced β-cell apoptosis. In conclusion, JNK1 signaling plays an essential role in macrophage induced β-cell apoptosis and the development of hyperglycemia in MLD-STZ induced pancreatic injury.     

Human urine-derived stem cells play a novel role in the treatment of STZ-induced diabetic mice

Human urine-derived stem cells (hUSCs) are a potential stem cell source for cell therapy. However, the effect of hUSCs on glucose metabolism regulation in type 1 diabetes was not clear. Therefore, the aim of the study was to evaluate whether hUSCs have protective effect on streptozotocin (STZ)-induced diabetes. hUSCs were extracted and cultivated with a special culture medium. Flow cytometry analysis was applied to detect cell surface markers. BALB/c male nude mice were either injected with high-dose STZ (HD-STZ) or multiple low-dose STZ (MLD-STZ). Serum and pancreatic insulin were measured, islet morphology and its vascularization were investigated. hUSCs highly expressed CD29, CD73, CD90 and CD146, and could differentiate into, at least, bone and fat in vitro. Transplantation of hUSCs into HD-STZ treated mice prolonged the median survival time and improved their blood glucose, and into those with MLD-STZ improved the glucose tolerance, islet morphology and increased the serum and pancreas insulin content. Furthermore, CD31 expression increased significantly in islets of BALB/c nude mice treated with hUSCs compared to those of un-transplanted MLD-STZ mice. hUSCs could improve the median survival time and glucose homeostasis in STZ-treated mice through promoting islet vascular regeneration and pancreatic beta-cell survival.     

Overexpression of PACAP in the pancreas failed to rescue early postnatal mortality in PACAP-null mice

PACAP exerts multiple activities as a hormone and neurotransmitter, and has been proposed to play vital roles in a variety of neuronal functions. PACAP is also involved in insulin secretion from pancreatic beta-cells. Recently, we and other groups demonstrated that PACAP-deficient mice (PACAP(-/-)) are viable, but suffer from increased postnatal mortality. To ascertain whether this high mortality is rescued by overexpression of PACAP in peripheral tissue (such as pancreas), we performed a genetic cross between PACAP(-/-) and our recently developed transgenic mice overexpressing PACAP in pancreatic beta-cells; and then examined the survival rate of their F2 progeny. PACAP(-/-) mice were segregated into two groups based on mortality as well as body weight gain: PACAP(-/-) that survived >20 days of age with normal weight gain and PACAP(-/-) that died before 20 days with a marked weight loss. Kaplan-Meier survival analysis demonstrated that PACAP(-/-) mice and those carrying the PACAP transgene have similarly lower survival probability compared with their heterozygous littermates that served as positive controls. Further study using additional tissue-specific transgenic or knockout mouse models will be required to determine the causative defects underlying the high mortality of PACAP(-/-) mice.     

Genomic sequencing of key genes in mouse pancreatic cancer cells

Pancreatic cancer is a multiple genetic disorder with many mutations identified during the progression. Two mouse pancreatic cancer cell lines were established which showed different phenotype in vivo: a non-metastatic cell line, Panc02, and a highly metastatic cell line, Panc02-H7, a derivative of Panc02. In order to investigate whether the genetic mutations of key genes in pancreatic cancer such as KRAS, TP53 (p53), CDKN2A (p16), SMAD4, ZIP4, and PDX-1 contribute to the phenotypic difference of these two mouse pancreatic cancer cells, we sequenced the exonic regions of these key genes in both cell lines and in the normal syngeneic mouse pancreas and compared them with the reference mouse genome sequence. The exons of KRAS, SMAD4, CDKN2A (p16), TP53 (p53), ZIP4, and PDX-1 genes were amplified and the genotype of these genes was determined by Sanger sequencing. The sequences were analyzed with Sequencher software. A mutation in SMAD4 was identified in both cell lines. This homozygote G to T mutation in the first position of codon 174 (GAA) generated a stop codon resulting in the translation of a truncated protein. Further functional analysis indicates that different TGF-β/SMAD signaling pathways were involved in those two mouse cell lines, which may explain the phonotypic difference between the two cells. A single nucleotide polymorphism (SNP) in KRAS gene (TAT to TAC at codon 32) was also identified in the normal pancreas DNA of the syngenic mouse and in both derived tumoral Panc02 and Panc02-H7 cells. No mutation or SNP was found in CDKN2A (p16), TP53 (p53), ZIP4, and PDX-1 genes in these two cell lines. The absence of mutations in genes such as KRAS, TP53, and CDKN2A, which are considered as key genes in the development of human pancreatic cancer suggests that SMAD4 might play a central and decisive role in mouse pancreatic cancer. These results also suggest that other mechanisms are involved in the substantial phenotypic difference between these two mouse pancreatic cancer cell lines. Further studies are warranted to elucidate the molecular pathways that lead to the aggressive metastatic potential of Panc02-H7.     

Absence of Diabetes and Pancreatic Exocrine Dysfunction in a Transgenic Model of Carboxyl-Ester Lipase-MODY (Maturity-Onset Diabetes of the Young)

Background

CEL-MODY is a monogenic form of diabetes with exocrine pancreatic insufficiency caused by mutations in CARBOXYL-ESTER LIPASE (CEL). The pathogenic processes underlying CEL-MODY are poorly understood, and the global knockout mouse model of the CEL gene (CELKO) did not recapitulate the disease. We therefore aimed to create and phenotype a mouse model specifically over-expressing mutated CEL in the pancreas.

Methods

We established a monotransgenic floxed (flanking LOX sequences) mouse line carrying the human CEL mutation c.1686delT and crossed it with an elastase-Cre mouse to derive a bitransgenic mouse line with pancreas-specific over-expression of CEL carrying this disease-associated mutation (TgCEL). Following confirmation of murine pancreatic expression of the human transgene by real-time quantitative PCR, we phenotyped the mouse model fed a normal chow and compared it with mice fed a 60% high fat diet (HFD) as well as the effects of short-term and long-term cerulein exposure.

Results

Pancreatic exocrine function was normal in TgCEL mice on normal chow as assessed by serum lipid and lipid-soluble vitamin levels, fecal elastase and fecal fat absorption, and the normoglycemic mice exhibited normal pancreatic morphology. On 60% HFD, the mice gained weight to the same extent as controls, had normal pancreatic exocrine function and comparable glucose tolerance even after resuming normal diet and follow up up to 22 months of age. The cerulein-exposed TgCEL mice gained weight and remained glucose tolerant, and there were no detectable mutation-specific differences in serum amylase, islet hormones or the extent of pancreatic tissue inflammation.

Conclusions

In this murine model of human CEL-MODY diabetes, we did not detect mutation-specific endocrine or exocrine pancreatic phenotypes, in response to altered diets or exposure to cerulein.     

The ability of pancreatic polypeptides (APP and BPP) to return to normal the hyperglycaemia, hyperinsulinaemia and weight gain of New Zealand obese mice.

Intraperitoneal injections of avian pancreatic polypeptide (APP) and bovine pancreatic polypeptide (BPP) are capable of returning to normal the hyperinsulinaemia, hyperglycaemia and weight gain of New Zealand obese mice. The lag glucose tolerance also becomes indistinguishable from normal. The mechanism whereby these polypeptides cause reversion is not known. Reversion can also be brought about by the intraperitoneal implantation of islets from white mice into New Zealand obese animals. The implanted islets secrete mouse pancreatic polypeptide. We conclude that the New Zealand obese syndrome arises from a genetic lack of mouse pancreatic polypeptide. We suggest that in humans a lack of pancreatic polypeptide might manifest as a syndrome analogous to that found in New Zealand obese mice.     

测定胰腺癌组织微血管密度及淋巴管密度的临床意义

目的:研究胰腺癌组织中微血管密度(Microvessel density,MVD)和淋巴管密度(Lymphatic vessel density,LVD)的变化、与胰腺癌临床病理的联系。方法:采用免疫组织化学SABC法应用CD34及D2-40分别检测41例胰腺导管腺癌患者配对癌组织内、癌旁及正常胰腺组织中MVD及LVD的表达情况,分析其与肿瘤分化程度、分期和淋巴转移间的相关性;以及癌组织MVD与癌旁组织LVD表达之间的关系。结果:在41例胰腺癌组织配对癌组织及正常胰腺组织平均MVD值分别为46.585±16.935,11.100±4.036,两组之间差别有统计学意义(P=0.000<0.01)。配对癌组织内、癌旁及正常胰腺组织中平均LVD值分别为11.244±4.800,15.829±7.470和13.512±5.139;其中癌旁组织与正常胰腺组织LVD值差别无统计学意义(P=0.060>0.05),癌旁组织与胰腺癌组织的LVD值有显著性差异(P=0.000<0.01)。癌组织内MVD值与癌旁组织LVD值之间有相关性(P=0.025<0.05)。结论:胰腺导管腺癌组织中MVD及LVD与肿瘤分化程度、病理分期及淋巴转移存在关联。胰腺癌组织内MVD值与癌旁组织LVD之间存在相关性。